Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26-week, multicenter, open, parallel clinical trial - HMR1964D/3001

Aventis Pharmaceuticals, Inc.0 个研究点目标入组 560 人开始时间: 2004年12月23日最近更新: 2012年5月1日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Aventis Pharmaceuticals, Inc.
入组人数: 560

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Girls or boys, 4 to 17 years of age, inclusive;
•- Girls are either not yet of childbearing potential (premenarchal) or, if sexually active, agree to use a reliable contraceptive measure for the duration of the study;
•- Type 1 diabetes mellitus as established in the medical history: for example but not limited to,
•. characterized by clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis…),
•. Glutamic Acid Decarboxylase (GAD) antibody indicative for type 1 diabetes measured at any time before the study,
•. requiring continuous insulin therapy from the time of diagnosis;
•- Onset of diabetes at least 1 year prior to visit 1 of the study;
•- Uninterrupted insulin therapy for at least one year prior to visit 1 of the study;
•- At visit 1, on a stable insulin regimen that consists of either NPH or insulin glargine as the basal insulin and willing to have multiple daily injections of insulin;
•- Glycated hemoglobin measured at visit 1 in the range of >= 6.0 and <=11.0 %;
•- Ability and willingness to perform blood glucose monitoring using the sponsor-provided blood glucose meter and subject diary.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•- Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation) during the study;
•- Diabetes other than type 1 diabetes mellitus;
•- Pregnancy (as determined by pregnancy blood test at visit 1) or breast feeding;
•- Pancreatectomised subjects;
•- Subjects who have undergone pancreas and/or islet cell transplants;
•- Treatment with any anti-diabetic oral agent at any time from the diagnosis of diabetes;
•- Treatment with systemic corticosteroids in the last month before visit 1;
•- Subjects who have been on pump therapy during the last 2 months before visit 1;
•- Subjects requiring excessively high doses of insulin (resistant patients), for example but not limited to subjects receiving over 150 IU per day;
•- Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol;
•- Treatment with any investigational drug in the last month before visit 1;
•- History of primary seizure disorders;
•- History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization or to care in the emergency ward, in the 3 months prior to visit 1;
•- History of hypoglycemia unawareness;
•- History of hypersensitivity to insulin or insulin analogs or any of the excipients in the insulin glulisine formulation (see the Global Investigator’s Brochure for a list of excipients) or any of excipients in the other study insulin preparations formulation;
•- Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult and would, in the opinion of the investigator, preclude the safe participation of the subject in this protocol;
•- History of cardiac abnormalities and/or cardiovascular disorders;
•- History of drug or alcohol abuse;
•- Impaired hepatic function, as shown by but not limited to alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age measured at visit 1;
•- Impaired renal function, as shown by but not limited to serum creatinine greater than 1.5 time the upper limit for age measured at visit 1;
•- Non fasting triglyceride level of >500 mg/dL (5.7 mmol/L) measured at visit 1;
•- Parent/legally authorized representative* unable to understand the nature, scope and possible consequences of the study;
•- Parent/legally authorized representative* unable to read and write;
•- Subjects unlikely to comply with protocol, e.g. an inability and unwillingness to participate in adequate training, an uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study;
•- Children or relatives of an employee of the sponsor or of sponsor representatives;
•- Children or relatives of the investigator, any subinvestigator, research assistant, pharmacist, study coordinator or other staff directly involved in the conduct of the protocol;
•- Subjects who have previously been treated with insulin glulisine.

研究者

发起方

Aventis Pharmaceuticals, Inc.

相似试验

进行中（未招募）

1 期

Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26-week, multicenter, open, parallel clinical trial - HMR1964D/3001Type 1 diabetes mellitus

EUCTR2004-000616-70-FIAventis Pharmaceuticals, Inc.560

进行中（未招募）

1 期

EUCTR2004-000616-70-GBAventis Pharmaceuticals, Inc.560

进行中（未招募）

不适用

EUCTR2004-000616-70-DEAventis Pharmaceuticals, Inc.560

进行中（未招募）

1 期

EUCTR2004-000616-70-HUAventis Pharmaceuticals, Inc.560

进行中（未招募）

1 期

EUCTR2004-000616-70-BEAventis Pharmaceuticals, Inc.560